TOKYO -- Asia accounts for less than 50% of the world's cancer patients but almost 60% of cancer deaths, partly due to lack of early detection.
SoftBank-affiliated Silicon Valley biotech venture Guardant Health thinks it can help. From a simple blood test, its diagnostic platform can identify a genetic mutation behind a patient's cancer in just a week. This lets the patient's doctor provide targeted treatment and paves the way for personalized medicine.
